News

Preliminary Results of the Epilepsy Trial. EGI announces preliminary results of case studies from the first three patients treated in its safety and feasibility trial for suppressing focal epilepsy with Geodesic Transcranial Electrical Neuromodulation (GTEN). Details.

Recorded webinar on high density EEG. On March 15, 2017, Dr. Mark Mintz delivered a webinar on the research as well as clinical applications of high density EEG and its accuracy in detecting abnormalities. This webinar was organized by ASET. You can view the recorded webinar online. Details. Register for this webinar at the ASET website.

High channel count EEG recommended as a quality standard for presurgical epilepsy workup. The working group on presurgical epilepsy diagnosis and operative epilepsy treatment has published their guidelines for quality standards for Austria, Germany, and Switzerland. The standards include video EEG with at least 64 channels and at least two other advanced imaging methods, including 64-256 channel EEG with source imaging. Access the paper.

Workshops, Schools, and Symposia

EGI Summer School 2017
Core dEEG Skills July 24-28 Foundations of Advanced dEEG Analysis Techniques July 31-Aug 2. Details. Register now.

Preliminary results of safety and feasibility for suppressing focal epilepsy with GTEN neuromodulation Brain Stimulation and Imaging Meeting Keynote address by Don Tucker, PhD and CEO of EGI. Saturday, 24 June. Details.

High-Resolution Electrical Head Models for Dense Array Neuromodulation
EGI Lunch Symposium at OHBM 2017 Tuesday, 27 June. Details. Register.

Conferences

Clinical Conferences
Research Conferences

research products button clinical products button

customer publication buttons clinical application button current manuals button

GTEN imageEGI introduces new GTEN 100 neuromodulation

Revealed at the Organization for Human Brain Mapping meeting in Geneva, EGI’s new GTEN 100 System is the most sophisticated non-invasive neuromodulation system on the market, introducing a new level of rigor and precision to this important field of research. EGI’s new GTEN 100 Neuromodulation System includes the ability to choose from 256 electrodes for tDCS, tACS, and tPCS neuromodulation with simultaneous EEG. Planning and targeting software incorporates high-definition electric head models, based on individual MRI scans if desired, for the highest level of precision. Available now for research use.
Read the news article. GTEN web page. Contact EGI for more information.

Read about the science behind GeoSource 3 source imaging and GTEN 100 neuromodulation.

SymposiaOnDemand buttonView EGI's GTEN Symposium presented at OHBM 2016.
See it now with EGI SYMPOSIA OnDemand. 

NEW! EGI's new study using GTEN 100 Research System and pulsed protocols showed long-term depression of motor cortex excitability, sustained over 90 minutes following current injection. Read the paper.

About EGI

EGI is a medical device company that designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity. A key component of these products is EGI’s proprietary dense array electroencephalography (dEEG) platform technology. The dense array method gathers brain activity data from many more electrodes than conventional EEG products (up to 256), generating significantly higher quality and more precise levels of information. With regulatory clearance in the US, EU and a number of other major international regulatory bodies, the Company’s technology has been increasingly adopted as a powerful research tool and more recently as a cost effective and patient friendly clinical neurodiagnostic platform.

advamed sm logo